Status:

COMPLETED

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)

Lead Sponsor:

Institute of Tropical Medicine, Belgium

Collaborating Sponsors:

Damien Foundation

Conditions:

Leprosy

Eligibility:

All Genders

5+ years

Phase:

PHASE2

Brief Summary

This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which...

Detailed Description

Given the fact that the investigators are going to provide to healthy people a drug that has not been used before for this indication and which has only been conditionally approved for use in multi-dr...

Eligibility Criteria

Inclusion

  • Being a permanent resident of the study village, in good state of health
  • Able and willing to provide informed consent
  • Age 5 years or above and weight of 20 kg or above

Exclusion

  • Signs of active leprosy
  • Signs of active pulmonary tuberculosis (cough ≥2 weeks duration)
  • Signs of active extra-pulmonary tuberculosis (bluish-red nodules that cover the lymph nodes, bones or joints, or cervical glands with discharge)
  • History of liver- or kidney disease
  • Allergy to rifampicin or bedaquiline
  • Having received rifampicin or bedaquiline (if applicable) in the last 2-year period
  • Not able to swallow bedaquiline 100 mg tablets
  • Self-reported (suspected) pregnancy or breastfeeding
  • Concurrent (within the last three week period before D0) use of medications not included in the safe list (for bedaquiline only)
  • QT-prolongation of ≥450 msec in baseline ECG within the last week.
  • Jaundice or self-reported liver function abnormalities or hepatitis
  • Value of baseline ALT or AST \>3x ULN within the last week. In case only ALT is available, this would suffice for enrollment

Key Trial Info

Start Date :

July 14 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 26 2023

Estimated Enrollment :

313 Patients enrolled

Trial Details

Trial ID

NCT05406479

Start Date

July 14 2022

End Date

January 26 2023

Last Update

August 28 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fondation Damien

Gege, Ndzuwani, Comoros